Entrada Therapeutics announced that an independent Data Monitoring Committee has recommended advancing to Cohort 3 at the top dose of 18 mg/kg in their Phase 1/2 ELEVATE-44-201 clinical trial for ENTR-601-44, a potential treatment for Duchenne muscular dystrophy (DMD). This follows positive safety and pharmacokinetic data from Cohort 2, which used a 12 mg/kg dose. The higher dose aims to increase drug exposure and dystrophin production, potentially improving patient outcomes. Data from Cohort 1's open-label period is expected by the end of 2026, with Cohort 2 results due in early 2027, marking important steps in the drug's development.
Entrada Therapeutics' clinical trial update comes as the Health sector on Pluang shows broad gains, with 103 of 150 US stocks rising as of Oct 14, 2026 18:11 WIB. Notable movers include Liquidia Corporation (LQDA) up 52.74% to USD 40.95, Abeona Therapeutics (ABEO) up 10.62% to USD 5.00 with a typical hold time of 26 days, and Brookdale Senior Living (BKD) up 7.41% to USD 10.87. This snapshot reflects active trading and positive momentum in the Health sector on Pluang's platform.
Genesis Global won the Best AI Solution for Software Development award at the 2026 AI in Capital Markets Awards for its product Genesis Create. This software combines AI with reusable components and financial expertise to help firms develop productio...
nuVizz has been recognized as an Accelerator in the 2026 Nucleus Research Transportation Management Value Matrix for its specialized last-mile delivery technology. The platform excels in coordinating complex delivery networks involving private fleets...
ASML Holding posted a strong Q3 2026 earnings per share of $14.65, beating estimates of $12.17, driven by a 55% year-over-year sales growth and a 57.5% gross margin. Although revenue was slightly below expectations at $13.05 billion, the company bene...
Charles Schwab is set to report its Q3 2026 earnings with an estimated EPS of $1.66 and revenue around $7.18-$7.19 billion, reflecting significant growth driven by an 18.2% increase in trading revenue, net interest income, and asset management fees. ...
Transmission System Operators (TSOs) are increasingly investing in software like Energy Management Systems and grid planning tools to modernize aging infrastructure, enhance cybersecurity, and expand grid capacity. Cybersecurity remains their top con...
